• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Qualigen Therapeutics Appoints Shishir Sinha to Lead Diagnostics Division Following Promotion to Senior Vice President

    4/29/22 9:15:00 AM ET
    $QLGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QLGN alert in real time by email

    CARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, announces today that it has appointed Shishir Sinha, the Company's newly promoted Senior Vice President and current Chief Operating Officer, to lead the Company's diagnostics division.

    "Shishir's consistent leadership as chief operating officer has been an essential part of our strategy to date. With the return of the sales and marketing of FastPack® last month, our diagnostics business is an essential asset to the strategic success of the Company. Therefore, it is only fitting that we now entrust Shishir with implementing our plans to grow and evolve our diagnostics business," commented Michael Poirier, Qualigen's Chief Executive Officer and Chairman. "We are confident in Shishir's leadership to drive growth and technological development in this cornerstone of our business operations."

    "Qualigen's future as a diversified life sciences company is grounded in its roots as an operating diagnostics company, and the diagnostics arm of the Company has the greatest potential for growth in the short term. I take seriously the responsibility of guiding the business into this new era and will work closely with our talented diagnostics team to continue to increase sales and our worldwide distribution footprint, provide patients and clinicians with high quality and innovation, and deliver measurable value to our shareholders," added Mr. Sinha.

    About Qualigen Therapeutics, Inc.

    Qualigen Therapeutics, Inc. is a diversified life sciences company focused on developing treatments for adult and pediatric cancer, as well as maintaining and expanding its core FDA-cleared FastPack® System, which has been used successfully in diagnostics for over 20 years. Our investigational QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against "unwinding," help inhibit cancer cell proliferation. Our investigational QN-247 compound inhibits nucleolin, a key multi-functional regulatory protein that is overexpressed in cancer cells; QN-247 may thereby be able to inhibit the cells' proliferation. QN-247 has shown promise in preclinical studies for the treatment of acute myeloid leukemia (AML). The investigational compounds within Qualigen's RAS-F family of RAS oncogene protein-protein interaction inhibitor small molecules are believed to inhibit or block the binding of mutated RAS genes' proteins to their effector proteins, thereby leaving the proteins from the mutated RAS unable to cause further harm. In theory, such mechanism of action may be effective in the treatment of about one quarter of all cancers, including certain forms of pancreatic, colorectal, and lung cancers. In addition to its oncology drug pipeline, Qualigen has an established diagnostics business which manufactures and distributes proprietary and highly accurate rapid blood testing systems to physician offices and small hospitals for the management of prostate cancer and other diseases and health conditions.

    For more information about Qualigen Therapeutics, Inc., please visit www.qualigeninc.com.

    Forward-Looking Statements

    This news release contains forward-looking statements by Qualigen that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. These statements include those related to the Company's prospects and strategy for the Company's diagnostics business and its development of therapeutic drug candidates. Actual events or results may differ from the Company's expectations. For example, there can be no assurance that the Company will be able to maintain its diagnostic sales and marketing engine without interruption following the expiration of the distribution agreement with Sekisui Diagnostics, compete with others in this industry or expand market demand and/or market share for its diagnostics product, nor can there be any assurance that the Company will be able to successfully develop any drugs (including QN-302, QN-247 and RAS-F); that preclinical development of the Company's drugs (including QN-302, QN-247 and RAS-F, and the deprioritized infectious-disease drug candidate QN-165) will be completed on any projected timeline or will be successful; that any clinical trials will be approved to begin by or will proceed as contemplated by any projected timeline, or at all; that any future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts; that any drugs will receive required regulatory approvals (or Fast Track designation or Orphan Drug status) or that they will be commercially successful; that patents will issue on the Company's owned and in-licensed patent applications; that such patents, if any, and the Company's currently owned and in-licensed patents would prevent competition; or that the Company will be able to procure or earn sufficient working capital to complete the development, testing and launch of the Company's prospective therapeutic products (including QN-302, QN-247 and RAS-F, and QN-165). The Company's stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fails to occur or is delayed or if any actual future event otherwise differs from expectations. Additional information concerning these and other risk factors affecting the Company's business can be found in the Company's prior filings with the Securities and Exchange Commission, including its most recent Form 10-K, all of which are available at www.sec.gov.

    The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

    Contact:

    Jules Abraham

    JQA Partners, Inc.

    917-885-7378

    [email protected]

    Source: Qualigen Therapeutics, Inc.



    Primary Logo

    Get the next $QLGN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $QLGN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QLGN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Qualigen Therapeutics Inc.

      10-Q - Qualigen Therapeutics, Inc. (0001460702) (Filer)

      7/21/25 5:27:03 PM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Qualigen Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Qualigen Therapeutics, Inc. (0001460702) (Filer)

      7/16/25 9:28:08 AM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Qualigen Therapeutics Inc.

      10-K - Qualigen Therapeutics, Inc. (0001460702) (Filer)

      6/30/25 5:28:36 PM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QLGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Bensler Graydon

      3 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)

      11/15/24 4:05:33 PM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Braeden Lichti

      3 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)

      10/17/24 4:05:15 PM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Lim Robert Bradley

      3 - Qualigen Therapeutics, Inc. (0001460702) (Issuer)

      8/9/24 4:01:09 PM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QLGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Qualigen Granted New Patents Covering 25 Countries

      CARLSBAD, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company" or "Qualigen") is announcing an update on patents granted in the first six months of 2025. The patent is Titled "Substitued Naphthalene Diimides and Their Use." The patent is for the drug, which was developed by Professor Stephen Neidle and his team at the University College of London, and is licensed by Qualigen Therapeutics, QN-302. These patents cover the product and their methods of manufacturing. Through validations and process across Europe these patents were granted and cover the majority of the Euoprean population. In total over 20 countries in Europe have patent coverage f

      7/16/25 8:00:00 AM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

      CARLSBAD, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") on May 19, 2025 (the "Notice"). The Notice indicated that the Nasdaq Hearings Panel (the "Panel") will consider the Company's failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025 as an additional basis for delisting the Company's securities from The Nasdaq Stock Market. This matter serves as an additional deficiency under Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all

      5/19/25 5:25:00 PM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K

      CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") on April 24, 2025 (the "Notice"). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c) (the "Listing Rule") as a result of its failure to timely file its Annual Report on Form 10-K for the annual period ended December 31, 2024 (the "2024 Form 10-K"), as described more fully in the Company's Form 12b-25 Notification of Late Filing (the "Form 12b-25") filed with the Securities and Exchange Co

      5/1/25 4:20:00 PM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QLGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Qualigen Therapeutics, Inc. Announces management changes.

      CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (the "Company") announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors of the Company (the Board") of his intention to resign as chief executive officer and Chairman of the Board of the Company, effective immediately. On the same date, Mr. Christopher Lotz, Chief Financial Office also tendered his resignation from the company, effective immediately. Both resignations were attributed to disagreements with the Company regarding its future direction and strategic initiatives. On September 25, 2024, the board of directors appointed Campbell Becher as President of the

      9/26/24 5:10:00 PM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Qualigen Therapeutics Appoints Shishir Sinha to Lead Diagnostics Division Following Promotion to Senior Vice President

      CARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, announces today that it has appointed Shishir Sinha, the Company's newly promoted Senior Vice President and current Chief Operating Officer, to lead the Company's diagnostics division. "Shishir's consistent leadership as chief operating officer has been an essential part of our strategy to date. With the return of the sales and marketing of FastPack® last month, our diagnostics business is an essential asset to t

      4/29/22 9:15:00 AM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Qualigen Therapeutics, Inc. Appoints Tariq Arshad, MD, MBA as Chief Medical Officer

      New Position Created to Deepen Clinical Expertise and Advance Pipeline Therapeutic Programs CARLSBAD, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, today announced the appointment of Tariq Arshad, MD, MBA to the newly-created position of Senior Vice President, Chief Medical Officer. Dr. Arshad brings more than 20 years of biotech and pharmaceutical experience to Qualigen Therapeutics during a dynamic time of growth and implementation of long-range strategy. "We are delighted to welcome Tariq to Qualigen as our Chief Medical Off

      5/19/21 7:30:00 AM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QLGN
    Financials

    Live finance-specific insights

    See more
    • Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023

      Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack® diagnostics business for approximately $5 million in all cash transaction to support advancement of therapeutics pipeline CARLSBAD, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces financial results for the second quarter ending June 30, 2023, and provides a corporate update: Highlights For Second Quarter and To Date 2023: Therapeutics Highlights: QN-

      8/15/23 8:30:00 AM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023

      Company Reports 123% Increase in Year-Over-Year Revenue CARLSBAD, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces financial results for the first quarter ending March 31, 2023, and provides a corporate update. Highlights For First Quarter and To Date 2023: Therapeutics Highlights: QN-302 Orphan Drug Designation granted by FDA for the intended indication of pancreatic cancerGood laboratory practice (GLP) toxicology studies initiatedComposition

      5/16/23 8:00:00 AM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

      CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN, Inc.))), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces financial results for the fourth quarter and fiscal year ended December 31, 2022, and provides an update on the company's therapeutics pipeline and other corporate developments. Highlights For 2022 and to Date: Therapeutics Highlights: QN-302 Secured worldwide rights to G4-selective transcription inhibitors from University College London to develop as cancer therapeuticsEngaged QN

      5/2/23 4:30:00 PM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QLGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Qualigen Therapeutics Inc. (Amendment)

      SC 13G/A - Qualigen Therapeutics, Inc. (0001460702) (Subject)

      5/27/22 9:22:10 AM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Qualigen Therapeutics, Inc.

      SC 13G - Qualigen Therapeutics, Inc. (0001460702) (Subject)

      12/6/21 5:04:28 PM ET
      $QLGN
      Biotechnology: Pharmaceutical Preparations
      Health Care